Navigation Links
Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
Date:1/6/2011

es, including an increased risk for kidney dysfunction and cardiovascular disease.

In 2008, approximately 8.3 million patients in the U.S., 6.4 million patients in the European Union and 2.9 million patients in Japan were diagnosed with gout.  Gout is the most common form of inflammatory arthritis in men over the age of 40 and represents a significant unmet medical need with limited treatment options.

About RDEA594Our most advanced product candidate for the treatment of hyperuricemia and gout, RDEA594, is an oral, once-daily inhibitor of URAT1, a transporter in the kidney that regulates uric acid excretion from the body.  Approximately 90% of gout patients are considered to be under-excretors of uric acid, and recent studies have shown that defects in renal transporters have been genetically linked to gout.  Consequently, increasing renal excretion of uric acid by moderating URAT1 transporter activity may provide the most physiologically appropriate treatment for gout.  In addition, because increasing the excretion of serum uric acid is additive to the effects of drugs that decrease the production of uric acid, such as allopurinol and febuxostat, RDEA594 in combination with such drugs has the potential to treat the significant portion of the gout population that is not adequately treated with existing therapies.

RDEA594 is in Phase 2 development as a single agent and in combination with the approved xanthine oxidase inhibitor, allopurinol.  Over 500 people have received RDEA594 in Phase 1 and 2 clinical trials.

About Ardea Biosciences, Inc. Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases.  RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a once-daily, oral inhibitor of the URAT1 transporter inhibitor in Phase 2 clinical development.  Our
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Ardea Biosciences to Present at Two Upcoming Investor Conferences
2. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
3. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
4. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
5. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
6. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
7. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
8. Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting
9. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
10. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
11. Whitney M. Young, Jr. Health Services and Magellan Biosciences Partner to Provide Three-Minute LeadCare II Blood-Lead Screenings to Berlin Elementary Students
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... NC (PRWEB) November 25, 2014 ... Intensity Focused Ultrasound (HIFU) devices, recently participated in ... Small Renal Mass 360° .” Key opinion leaders ... therapeutic advances related to small renal masses while ... about different ablative technologies in hands-on labs. Attendees ...
(Date:11/26/2014)... Miles Holder, formerly of Micron Research and ... team as Sales/Marketing Manager. Mr. Holder has over 25 ... the graphite industry. , “We are thrilled to be ... Trinkley, VP of Market and Product Development for Graphel ... the graphite industry, along with his proven track record ...
(Date:11/26/2014)... 2014 Bio-Techne Corporation (NASDAQ: TECH ... Gavin to serve in a newly created position ... Mr. Gavin will be responsible for managing the operations ... ProteinSimple business acquired in July 2014 and the recently ... California -based ProteinSimple develops and commercializes proprietary systems ...
(Date:11/24/2014)... , Nov. 24, 2014  Last week, Representatives ... Butterfield (D-NC) took a bold bipartisan step ... introducing the OPEN Act. Original co-sponsors of the ... The Act will incentivize drug makers and innovators ... diseases and pediatric cancers, which opens the door ...
Breaking Biology Technology:SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
... SAN DIEGO, Sept. 27, 2011 Verenium Corporation (Nasdaq: ... developing and commercializing high-performance enzymes, today announced that it ... an aggregate of $34.9 million in principal amount of ... repurchase of approximately $1.1 million in principal amount of ...
... Circassia Ltd, a specialty biopharmaceutical company focused ... results showing that its ToleroMune® hay fever vaccine ... on placebo.  The treatment was extremely well tolerated. ... phase II study conducted in 50 hay fever ...
... Chemical Engineering department and the Kavli institute of Delft ... electrons can move freely in layers of linked semiconductor ... will be very useful for the development of cheap ... their findings on Sunday 25 September on the website ...
Cached Biology Technology:Verenium Announces Debt Repurchase 2Verenium Announces Debt Repurchase 3Circassia's Hay Fever Treatment Improves Patients' Allergy Symptoms in Phase II Clinical Trial 2Circassia's Hay Fever Treatment Improves Patients' Allergy Symptoms in Phase II Clinical Trial 3TU Delft: cheap and efficient solar cell made possible by linked nanoparticles 2
(Date:11/10/2014)... on U.S. store shelves in early 2010, and people ... small packets can be tossed into a washing machine ... powder. The convenience, though, has come with risks for ... Nationwide Children,s Hospital found that from 2012 through 2013, ... younger than 6 years of age swallowing, inhaling, or ...
(Date:11/6/2014)... groundbreaking paper from a team of Florida State University ... plants could adapt to and survive environmental swings such ... the latest issue of the journal The Plant ... of DNA and proteins) is organized in a cell ... genes are turned on and others are turned off. ...
(Date:11/5/2014)... of biology in the UTSA College of Sciences, ... selected to receive a two-year $300,00 National Science ... (EAGER). The funding supports President Obama,s BRAIN Initiative, ... new technology that will demystify complex brain processes. ... neuroscience are broken into the interactions of multiple ...
Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Maize analysis yields whole new world of genetic science 2UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3
... WORCESTER, MA Scientists at the University of Massachusetts ... piecing together the short DNA reads produced by next-generation ... genome sequences. Job Dekker, PhD, and colleagues have shown ... accurately by measuring the frequency of interactions between DNA ...
... great number of women experience depression or anxiety while ... mood disorders may lead to long-term emotional and behavioral ... the fetal environment has a strong influence on offspring ... exact mechanisms by which this occurs are not completely ...
... 2013, Cleveland: Cleveland Clinic researchers Richard A. Padgett, Ph.D., and ... American Association for the Advancement of Science (AAAS). This year,s ... & Notes section of the journal Science on ... Department of Molecular Genetics at the Lerner Research Institute, was ...
Cached Biology News:University Of Massachusetts Medical School scientists re-imagine how genomes are assembled 2University Of Massachusetts Medical School scientists re-imagine how genomes are assembled 32 Cleveland Clinic researchers honored for contribution to science 2
Recombinant Mouse Noggin...
Human VASA Biotinylated Affinity Purified PAb...
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
... Complete kit for all types of yeast two-hybrid studies, ... Choice of two bait vectors ... , Triple reporter ... Complete set of controls: ...
Biology Products: